Abingdon Health Ltd a specialist medical diagnostics company, today announces the completion of a £3 million investment round led by Imperial Innovations.
The fundraising will support the commercialisation of the Group’s recently launched products in the area of multiple myeloma testing, specifically Seralite®‐ FLC Serum. These assays allow for the rapid quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) as an aid to the diagnosis and management of multiple myeloma. On 27 June 2016, Abingdon Health announced that it had entered into a multi-year, exclusive, global distribution agreement with Sebia for Seralite®-FLC Serum. Sebia is the world leader in medical diagnostics by capillary electrophoresis.
Chris Yates, CEO of Abingdon Health, commented: “The successful completion of this funding round, coupled with the recent announcement of the global distribution agreement with Sebia, are significant milestones for the Group, and will support the commercialisation of its Seralite®– FLC assays.”